I imagine these folks are endorsing the company, eh?
Additional Speakers will include Oliver Sartor, M.D., Louisiana State University Health Sciences Center; Thomas McKearn, M.D., Ph.D., GPC Biotech, Inc.; Alfred Witjes, M.D., Ph.D., UMC Nijmegen, the Netherlands and Jurgen Engel, Ph.D. Executive Vice-President, Global Research & Development and Chief Operating Officer, AEterna Zentaris Inc.
Also, the sale of securities (35,965,000) last quarter will finance some of the final plays on the announced trials, imo.
As of June 30, 2005, we had seven proprietary drug product candidates under development: satraplatin, EOquin ™, elsamitrucin, ozarelix (formerly SPI-153), lucanthone, RenaZorb™, and SPI-1620, and through the date of this report have filed eleven ANDAs with the FDA, including those for ciprofloxacin tablets and carboplatin injection, which have been approved by the FDA. We are developing our proprietary drug product candidates for the treatment of a variety of cancers and other unmet medical needs. We are also active in filing ANDAs with the FDA seeking approval for marketing generic versions of branded prescription drugs whose patent protection has either already expired or is scheduled to expire in the foreseeable future. In addition, we have a few neurology compounds that we may out-license to third parties for further development.
Plus, the relationship with CURA has yet to be realized, imo. It was just established this year, so I expect by end of year to see revenues from it.
Market Data 
Markets 
AI
